Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.
暂无分享，去创建一个
J. Blay | F. Bertucci | S. Chevret | A. Le Cesne | I. Ray-Coquard | L. Gambotti | P. Soulié | J. Lotz | T. Valentin | N. Penel | C. Massard | E. Bompas | M. Brahmi | D. Tosi | P. Boudou-Rouquette | S. Cousin | Z. Neviere | M. Cancel | T. Ryckewaert | P. Soibinet | C. Even | A. Lamrani-Ghaouti | C. Simon | Esma Saada Bouzid | Frédéric Legrand